Half Year Trading Update
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.
Optima Health plc
(“Optima”, the “Company”, and, together with its subsidiaries, the “Group”)
Half Year Trading Update
First-half delivery of 60% increase in revenues, reflecting the successful integration of PAM Healthcare and continued growth across the Group
LONDON, UK, 20 October 2026, Optima Health (AIM: OPT), the UK’s leading provider of technology enabled corporate health and wellbeing solutions, today provides a trading update ahead of publication of the Group’s unaudited results for the half year ended 30 September 2026 (“H1 27” or the “Period”).
Highlights
- H1 FY27 revenue expected to be approximately £96 million, c.60% ahead of the prior year period (H1 FY26: £59.5 million), reflecting the acquisition of PAM Healthcare and continued growth across the Group's core operations.
- Trading remains in line with the Board's expectations.
- PAM Healthcare integration progressing to plan, with operational and commercial synergies being realised.
- New business wins in the first half of an annualised £10.6 million (H1 FY26: £1.9 million).
- New contract win secured with HMRC.
- Adjacent market contract secured supporting delivery of the Home Office-procured Support for Victims of Modern Slavery programme.
- Strong pipeline of opportunities across public and private sector markets.
- Robust balance sheet with net debt (excluding leases) of £70.4 million as at 30 September 2026 (£94.4 million at 31 March 2026).
- Remains on track to deliver FY27 results in line with current market expectations
Optima is pleased to report revenue for the first half of FY27 is expected to be approximately 60% ahead of the prior year period at £96 million, reflecting the contribution from the acquisition of PAM Healthcare completed in March 2026, together with continued growth across the Group's occupational health and wellbeing operations.
Trading during the period was in line with the Board's expectations. The integration of PAM Healthcare continues to progress to plan, with operational and commercial synergies being realised across the enlarged Group, and demand across the Group's core markets remaining resilient throughout the period. The Board therefore continues to expect full year FY27 results to be in line with market expectations.
The Group secured a number of contract awards during the period, notably a new programme with HMRC, together with an adjacent market win supporting delivery of the Home Office-procured Support for Victims of Modern Slavery contract. Annualised new business wins equates to £10.6 million.
The Group continues to focus on cash generation and deleveraging following the acquisition of PAM Healthcare in March 2026 and remains well positioned to execute its growth strategy. The Group’s unaudited net debt position (excluding leases) at 30 September 2026 was £70.4 million, comprised of a cash balance of £11.6 million, and £82 million of debt.
Optima expects to report its Interim Results for the six months ended 30 September 2026 by December 2026.
Jonathan Thomas, Chief Executive Officer of Optima Health, said:
“We have delivered a strong first-half performance, with revenue expected to be approximately 60% ahead of the prior year period, reflecting the successful integration of PAM Healthcare and continued growth across the Group.
“We are particularly encouraged by the progress being made across the enlarged business. Integration is advancing well, synergy delivery remains on track and we continue to see demand for our services across both public and private sector markets.
“During the period, we secured a number of important new contract awards, including with HMRC, and our support of the Home Office-procured Support for Victims of Modern Slavery programme. These wins demonstrate the strength of our market position, the breadth of our capabilities and the opportunities available to the Group as we continue to expand into adjacent markets.
We enter the second half of the year with a strong pipeline of opportunities, increasing operational momentum and confidence in the Group's outlook. The Board remains focused on delivering sustainable growth and creating long-term value for all stakeholders.”
Enquiries
Optima Health
Jonathan Thomas, CEO
Andy Bones, Interim CFO
+44(0)3300085113
media@OptimaHealth.co.uk
Nominated Adviser and Corporate Broker
Panmure Liberum Limited
Emma Earl / Will Goode / Mark Rogers
Rupert Dearden
Joint Corporate Broker
Cavendish Capital Markets
Geoff Nash / Ben Jeynes / George Lawson /Julian Morse / Michael Johnson/ Nigel Birks
+44 (0)20 3100 2000
UK Financial PR Adviser
ICR Healthcare
Mary-Jane Elliott / Chris Welsh / Lindsey Neville
optimahealth@icrinc.com
About Optima Health
Optima Health is the UK and Ireland’s leading provider of occupational health and wellbeing services, delivering clinically led, technology-driven solutions to organisations across the public and private sectors. The Group employs more than 1,250 clinicians directly, supported by a wider network of more than 1,000 subcontracted associate clinicians, and delivers more than one million interventions each year across a national network of clinics.
For more information visit www.optimahealth.co.uk or www.optimahealth.ie
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDTSTUKSNRNRURAAA
